Acetyl Hexapeptide-3(Argireline®)

Acetyl Hexapeptide-3: Inhibits Wrinkle Formation

Argireline® is a unique new peptide that both reduces the degree of existing facial wrinkles and has been demonstrated effective against their development. It's been shown to inhibit the formation of the SNARE complex ( a core of membrane proteins that mediates neuronal exocytosis) as well as catecholamine release. These inhibitions confer anti-aging activity of Acetyl Hexapeptide-3(ARGIRELINE®); they closely relate to the basic biochemical mechanisms of winkle formation. Controlled studies have also demonstrated that facial wrinkle depth can be reduced, especially in the forehead and around eyes, and that Acetyl Hexapeptide-3(ARGIRELINE®) can prevent apparent facial skin ageing.

Cause of Facial Wrinkling

Facial wrinkling associated with aging is caused and exacerbated by many factors. Beyond the physiological pathways, molecular mechanisms involved in facial aging include changes in collagen conformation, elastin polypeptide degradation, and problems of the skin's lipid matrix. Recent studies clearly establish that these changes can be significantly reduced by inhibiting SNARE complex formation.

The Technology

Acetyl Hexapeptide-3(ARGIRELINE®)'s specific sequence was shown to inhibit the SNARE complex formation and catecholamine release. Once identified, it was synthesized by solid phase peptide synthesis and then purified and characterized.

Efficacy Testing

In clinical testing, emulsion containing 10% of Acetyl Hexapeptide-3(ARGIRELINE®) solution applied twice a day around eyes. It was observed that severity of wrinkles around eyes decreased up to 17% after 15days of treatment and up to 27% after 30days of treatment, sustaining the proposed biochemical mechanism hypothesis.

In VIVO Testing

The skin replicas below show the improvement in facial smoothness at 30 days post Acetyl Hexapeptide-3(ARGIRELINE®) treatment, compared with results obtained without the incorporation of Acetyl Hexapeptide-3(ARGIRELINE®) solution into the test cream.

Case 1: Treated with an Acetyl Hexapeptide-3 containing cream after 30 days

Case 2: Treated with an Acetyl Hexapeptide-3 containing cream after 30 days